These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 22905673)
21. [Bioavailability of a delayed-action aminophylline preparation]. Regazzi MB; Guarnone E; Bartoli A; Ciardelli L; Piacentini P Minerva Med; 1985 Mar; 76(13):641-5. PubMed ID: 3991030 [TBL] [Abstract][Full Text] [Related]
22. An investigation into effects of in vitro test condition on the release properties of theophylline from HPMC matrices using factorial design. Petrovic A; Ibric S; Trajkovic S; Popovic R; Djuric Z; Popadic D Arch Pharm Res; 2009 Jul; 32(7):1087-96. PubMed ID: 19641891 [TBL] [Abstract][Full Text] [Related]
23. Development of an Extended-Release Formulation for Apremilast and a Level A in Vitro-in Vivo Correlation Study in Beagle Dogs. Tang M; Hu P; Huang S; Zheng Q; Yu H; He Y Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1607-1615. PubMed ID: 27568485 [TBL] [Abstract][Full Text] [Related]
24. In vitro and in vivo evaluation of single-unit commercial conventional tablet and sustained-release capsules compared with multiple-unit polystyrene microparticle dosage forms of Ibuprofen. Tamilvanan S; Sa B AAPS PharmSciTech; 2006 Sep; 7(3):72. PubMed ID: 17025252 [TBL] [Abstract][Full Text] [Related]
25. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels. Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of hydrophilic matrix tablets based on Carbopol(®) 971P and low-viscosity sodium alginate for pH-independent controlled drug release. Al-Zoubi NM; AlKhatib HS; Obeidat WM Drug Dev Ind Pharm; 2011 Jul; 37(7):798-808. PubMed ID: 21247372 [TBL] [Abstract][Full Text] [Related]
27. Preparation and evaluation of novel metronidazole sustained release and floating matrix tablets. Asnaashari S; Khoei NS; Zarrintan MH; Adibkia K; Javadzadeh Y Pharm Dev Technol; 2011 Aug; 16(4):400-7. PubMed ID: 20429828 [TBL] [Abstract][Full Text] [Related]
28. Preparation of delayed release tablet dosage forms by compression coating: effect of coating material on theophylline release. El-Malah Y; Nazzal S Pharm Dev Technol; 2010 Jun; 15(3):305-10. PubMed ID: 22716471 [TBL] [Abstract][Full Text] [Related]
29. Correlation of drug release with pulmonary drug absorption profiles for nebulizable liposomal formulations. Beck-Broichsitter M; Rieger M; Reul R; Gessler T; Seeger W; Schmehl T Eur J Pharm Biopharm; 2013 May; 84(1):106-14. PubMed ID: 23262166 [TBL] [Abstract][Full Text] [Related]
30. In vitro quantitative ((1))H and ((19))F nuclear magnetic resonance spectroscopy and imaging studies of fluvastatin™ in Lescol® XL tablets in a USP-IV dissolution cell. Zhang Q; Gladden L; Avalle P; Mantle M J Control Release; 2011 Dec; 156(3):345-54. PubMed ID: 21911016 [TBL] [Abstract][Full Text] [Related]
31. Microencapsulation studies on aminophylline involving spherical crystallization, spheronization and drug loading on to non-pareil seeds. Boles MG; Deasy PB; Donnellan MF J Microencapsul; 1994; 11(1):55-67. PubMed ID: 8138875 [TBL] [Abstract][Full Text] [Related]
32. Evaluation of hydrophilic, hydrophobic and waxy matrix excipients for sustained release tablets of venlafaxine hydrochloride. Yadav K; Yadav D; Srivastava AK Drug Dev Ind Pharm; 2013 Aug; 39(8):1197-206. PubMed ID: 22803761 [TBL] [Abstract][Full Text] [Related]
33. Design and study of lamivudine oral controlled release tablets. Ravi PR; Ganga S; Saha RN AAPS PharmSciTech; 2007 Dec; 8(4):E101. PubMed ID: 18181522 [TBL] [Abstract][Full Text] [Related]
34. Bioavailability enhancement of baclofen by gastroretentive floating formulation: statistical optimization, in vitro and in vivo pharmacokinetic studies. Thakar K; Joshi G; Sawant KK Drug Dev Ind Pharm; 2013 Jun; 39(6):880-8. PubMed ID: 22901056 [TBL] [Abstract][Full Text] [Related]
35. Novel mathematical method for quantitative expression of deviation from the higuchi model. Gohel MC; Panchal MK; Jogani VV AAPS PharmSciTech; 2000 Oct; 1(4):E31. PubMed ID: 14727896 [TBL] [Abstract][Full Text] [Related]
36. Utility of PBPK Absorption Modeling to Guide Modified Release Formulation Development of Gaboxadol, a Highly Soluble Compound With Region-Dependent Absorption. Kesisoglou F; Balakrishnan A; Manser K J Pharm Sci; 2016 Feb; 105(2):722-728. PubMed ID: 26457884 [TBL] [Abstract][Full Text] [Related]
37. The use of an in vitro dissolution and absorption system to evaluate oral absorption of two weak bases in pH-independent controlled-release formulations. Sugawara M; Kadomura S; He X; Takekuma Y; Kohri N; Miyazaki K Eur J Pharm Sci; 2005 Sep; 26(1):1-8. PubMed ID: 15961297 [TBL] [Abstract][Full Text] [Related]
38. Biopharmaceutical characterization of sustained release matrix tablets based on novel carbomer polymers: formulation and in vivo investigation. Jelena P; Djurić Z; Jovanović M; Ibrić S; Kilibarda V; Jovanović D; Evic IK Eur J Drug Metab Pharmacokinet; 2005; 30(1-2):99-104. PubMed ID: 16010868 [TBL] [Abstract][Full Text] [Related]
40. Prediction of in vivo plasma concentration-time profile from in vitro release data of designed formulations of milnacipran using numerical convolution method. Singhvi G; Shah A; Yadav N; Saha RN Drug Dev Ind Pharm; 2015 Jan; 41(1):105-8. PubMed ID: 24164467 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]